Gerresheimer AG
ISIN: DE000A0LD6E6
WKN: A0LD6E
29 Juli 2026 04:56AM

EQS-News: Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

Gerresheimer AG · ISIN: DE000A0LD6E6 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2373126

EQS-News: Gerresheimer AG / Key word(s): Disposal/Strategic Company Decision
Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

29.07.2026 / 04:56 CET/CEST
The issuer is solely responsible for the content of this announcement.


Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

  • 16 production sites with around 2,400 employees in nine countries
  • Combined enterprise value of around EUR 1.5 billion
  • Significant optimization of the capital and financing structure through expected cash inflows, meaningfully decreasing leverage

Duesseldorf, Germany, July 29, 2026. Gerresheimer Glass Inc., USA, Gerresheimer Glas GmbH, Gerresheimer Group GmbH, and Gerresheimer AG (“Gerresheimer”), today entered into definitive agreements with an affiliate of funds advised by Apax Partners LLP (“Apax Funds”) regarding the sale of Centor US Holding Inc., USA, as well as Gerresheimer’s global Primary Packaging Plastics (PPP) business. The purchase price for the two business units combined is based on an enterprise value of approximately EUR 1.5 billion. The parties have agreed not to disclose further terms of the agreements. The transactions are subject to customary closing conditions and approvals and will be closed independently of one another.The sale of Centor is expected to close by the end of financial year 2026, while the sale of the global Primary Packaging Plastics business is expected to close in the first half of financial year 2027. Gerresheimer will use the expected cash inflows to significantly optimize its capital and financing structure by considerably decreasing its leverage.

“This transaction allows us to regain our strategic flexibility,” explains Uwe Röhrhoff, CEO of Gerresheimer AG. “At the same time, as a leading global partner to the pharmaceutical and biotech industries, we are focusing our business even more strongly on high-value drug delivery and medical devices, and primary packaging for injectable drugs.”

“Centor and Primary Packaging Plastics are market leaders in prescription vials and primary pharmaceutical packaging, built on a decades long reputation for quality and reliability. We have significant experience in carveouts and, together with our Operational Excellence Practice, we will work alongside management to establish a strong, standalone company positioned for long term growth,” says Anders Meyerhoff, Partner at Apax.

“Healthcare packaging plays a critical role in patient safety, with Centor’s and Primary Packaging Plastics’ products used to dispense medicines safely to millions of patients every day. As an independent company backed by the Apax Funds, the business will have the capital to invest in capacity, innovation and US expansion, building on its global leadership in healthcare packaging,” adds Mehmet Tar, Principal at Apax.

16 production sites in nine countries
The Apax Funds are acquiring the business providing packaging systems for dispensing prescription drugs in the U.S. and the global business for primary plastic packaging—representing a combined enterprise value of approximately 1.5 billion euros. In addition to the Centor site in the United States, the transaction includes a total of 15 production sites for primary plastic packaging in nine countries. In 2025, the two businesses generated combined revenue of approximately EUR 570 million with a total of around 2,400 employees.

Significant optimization of the capital and financing structure

“This transaction is an important milestone in optimizing our capital and financing structure, decreasing our leverage significantly,” says Wolf Lehmann, CFO of Gerresheimer AG. “We will use the expected cash inflows to accelerate our debt reduction. Together with the planned comprehensive refinancing, this will significantly reduce our interest expenses and achieve a sustainable capital structure. In addition, the continued implementation of our transformation program will also have a positive impact on our operating and free cash flow.”

Completion of the Centor sale before the end of this financial year

The transactions are subject to customary closing conditions and approvals. Gerresheimer expects to complete the sale of Centor by the end of financial year 2026. The sale of the global Primary Packaging Plastics business is expected to be completed in the first half of financial year 2027.
 

Morgan Stanley & Co. International plc is serving as lead financial advisor to Gerresheimer. Commerzbank also supports as financial advisor and has provided fairness opinions. Latham & Watkins is serving as legal counsel to Gerresheimer. 

 

About Apax

Apax is a global private equity advisory firm investing in mid-market businesses across the Technology, Services, and Internet/Consumer sectors. Combining the scale of a global firm with the focus of a sector specialist, Apax works with management teams to create long-term value through operational value creation. With more than 50 years of private equity experience in operational value creation, Apax has raised and advised funds with aggregate commitments of approximately $80 billion.
www.apax.com


About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

 

Contact Apax
Katarina Sallerfors
Head of Communications
T +44 207 666 6526
katarina.sallerfors@apax.com

 

Contact Gerresheimer

Media  
Jutta Lorberg
Group Senior Director Communication & Marketing
T +49 211 6181 264
jutta.lorberg@gerresheimer.com
Dersim Korkmaz
Corporate Communication
T +49 211 6181 296
dersim.korkmaz@gerresheimer.com
 
Investor Relations
 
Guido Pickert
Vice President Investor Relations
T +49 211 6181 220
gerresheimer.ir@gerresheimer.com 
 


29.07.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Gerresheimer AG
Peter-Müller-Str. 3
40468 Duesseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-121
E-mail: gerresheimer.ir@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 5299006GD4UWSYZOKC28
EQS News ID: 2373126

 
End of News EQS News Service

2373126  29.07.2026 CET/CEST

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2020 2021 2022 2023 2024 2025 2026e
Umsatzerlöse1 1.418,79 1.498,01 1.817,09 1.990,49 1.991,27 2.320,89 2.310,00
EBITDA1,2 310,14 306,31 340,87 399,42 364,59 312,91 390,00
EBITDA-Marge3 21,86 20,45 18,76 20,07 18,31 13,48 16,88
EBIT1,4 156,46 147,44 169,31 213,39 161,03 -209,32 200,00
EBIT-Marge5 11,03 9,84 9,32 10,72 8,09 -9,02 8,66
Jahresüberschuss1 89,88 87,24 102,19 120,09 84,34 -318,72 100,00
Netto-Marge6 6,34 5,82 5,62 6,03 4,24 -13,73 4,33
Cashflow1,7 222,19 212,08 221,94 294,34 238,95 209,53 0,00
Ergebnis je Aktie8 2,82 2,67 3,06 3,48 2,38 -9,27 1,80
Dividende8 1,25 1,25 1,25 1,25 0,04 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
Gerresheimer
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
A0LD6E DE000A0LD6E6 AG 951,23 Mio € 11.06.2007 Beobachten 9F387QG9+4J
* * *
KGV 2027e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
14,49 24,21 0,60 16,36 0,88 4,54 0,41
Dividenden
Dividende '2023
in €
Dividende '2024
in €
Dividende '2025e
in €
Div.-Rendite '2025e
in %
1,25 0,04 0,00 0,00%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
01.09.2026 16.04.2026 14.07.2026 15.10.2026 29.06.2026
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-1,01%
27,54 €
ATH 122,90 €
+2,14% +11,81% -0,15% -36,51% -31,15%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2026 · Made in Germany          
Die Analyse-Manufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 von Gereon Kruse #BGFL